Network Pharmacology Approach and Experimental Verification to Explore the Anti-NSCLC Mechanism of Grifolic Acid
International Journal of Molecular Sciences · 13.01.2025 · 26 (2) · 629
DOI: 10.3390/ijms26020629 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 13.01.2025. Verfasst von Xiangdan Cuan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Pu-Er Tea Science, Ministry of Education, Yunnan Agricultural University, Heilongtan, North of Kunming, Kunming 650201, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Network Pharmacology, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China,, the Yunnan Fundamental Research Project, the Research Start-up Fund of Yunnan Agricultural University.
Abstract (Originalsprache)
Lung cancer is the leading cause of cancer-related death. Non–small cell lung cancer (NSCLC) accounts for 85% of all lung cancers and over 60% express wild-type EGFR (WT-EGFR); however, EGFR tyrosine kinase inhibitors (TKIs) have limited effect in most patients with WT-EGFR tumors. In this study, we applied network pharmacology screening and MTT screening of bioactive compounds to obtain one novel grifolic acid that may inhibit NSCLC through the EGFR-ERK1/2 pathway. Through the PPI network and machine learning, we identified two hub genes, EGFR and AKT1, as potential therapeutic targets. Molecular docking confirmed that the grifolic acid could effectively bind to the key target, EGFR. Using the NSCLC cell line NCI-H1781 as an in vitro model, we evaluated the effect of the drugs’ combination on viability, apoptosis, and clonogenicity capacity. In vitro studies showed that combined treatment decreased cell viability, increased activation PARP, and caused cell cycle redistribution and significantly greater inhibition of pEGFR and pAKT. This study not only provides new insights into the mechanism of grifolic acid against NSCLC but also important information and new research ideas for the discovery of anti-NSCLC compounds from natural products.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Pu-Er Tea Science, Ministry of Education, Yunnan Agricultural University, Heilongtan, North of Kunming, Kunming 650201, China.
- College of Food Science and Technology, Yunnan Agricultural University, Heilongtan, North of Kunming, Kunming 650201, China.
- College of Science, Yunnan Agricultural University, Heilongtan, North of Kunming, Kunming 650201, China.
Förderung
- the National Natural Science Foundation of China,
- the Yunnan Fundamental Research Project
- the Research Start-up Fund of Yunnan Agricultural University
Zitieren
APA
Cuan, X., Wang, J., Zhao, Y., Yan, J., Sheng, J., & Huang, Y. (2025). Network Pharmacology Approach and Experimental Verification to Explore the Anti-NSCLC Mechanism of Grifolic Acid. International Journal of Molecular Sciences, 26(2), 629. https://doi.org/10.3390/ijms26020629
Vancouver
Cuan X, Wang J, Zhao Y, Yan J, Sheng J, Huang Y. Network Pharmacology Approach and Experimental Verification to Explore the Anti-NSCLC Mechanism of Grifolic Acid. International Journal of Molecular Sciences. 2025;26(2):629. doi:10.3390/ijms26020629
BibTeX
@article{Cuan2025,
author = {Cuan, Xiangdan and Wang, Jinxian and Zhao, Yue and Yan, Jingyun and Sheng, Jun and Huang, Yanping},
title = {Network Pharmacology Approach and Experimental Verification to Explore the Anti-NSCLC Mechanism of Grifolic Acid},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {2},
pages = {629},
doi = {10.3390/ijms26020629}
}
EUVIMED